|
Rib-X Pharmaceuticals Stage: Venture Date of Investment: 2003 Web Site : http://www.rib-x.com
|
 |
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. Rib-X has successfully completed two Phase II trials for two novel antibiotics against drug-resistant bacteria. Rib-X also has two discovery programs using its technology platform. Warburg Pincus led Rib-X’s Series B financing as well as two subsequent financings. The company was founded in 2000 around a scientific breakthrough pioneered by Yale University, the three-dimensional structure of a key antibiotic target, the ribosome. Using the proprietary high-resolution crystal structure of the ribosome, Rib-X’s discovery engine allows the visualization and prioritization of potential therapeutic antibiotic compounds. Rib-X can rationally design new drugs enabling breakthrough discoveries in an area where traditional drug discovery methods have not been as productive over the last thirty years.
